Targeting improved longevity and cancer through proteo-lipid vehicle delivery

The high cost of current advanced therapies remains a major barrier to their successful application in the more prevalent therapeutic areas and indications. David McCall, Senior Editor, BioInsights, talks to Matthew Scholz, Founder and Chief Executive Officer of Oisín Biotechnologies and OncoSenX, about novel approaches that can potentially unlock some of the largest unmet medical needs by patient population on a worldwide basis.

Please enter your email to access content Read now